000			03458nam a2200421 i 4500
999			_c112762 _d112762
001			112762
003			ES-MaUEC
005			20230209135224.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			181214s2019 gw a o |||| 0|eng d
020			_a9783319438962
024	7		_a10.1007/978-3-319-43896-2 _2doi
040			_bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC270.8 _b2019 EB
245	0	0	_aCancer Policy: Pharmaceutical Safety _cedited by June M. McKoy, Dennis P. West
264		1	_aCham _bSpringer International Publishing _c2019
300			_a1 recurso en línea (V, 128 páginas)
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aCancer Treatment and Research _x0927-3042 _v171
490	0		_aMedicine (Springer-11650)
505	0		_aPharmacovigilance programs: Do they improve Cancer Drug Safety? -- Impact of Cost on the Safety of Cancer pharmaceuticals -- Assessing pharmaceutical safety in Geriatric Oncology -- Cancer co-Morbidity: Implications for Drug Safety -- Statistical aids to signal generation: Are they effective in Identifying Adverse Cancer Drug Reactions? -- Pharmacovigilance of alternative medications in the Cancer Setting -- Key elements in Adverse Drug Interaction Safety Signals: evaluation of individual case reports in oncology -- Biosimilars: Are they really safe? -- Natural Language processing: improving the identification and communication of Cancer Drug Safety -- The Drug Shortage Crisis in the United States: Impact on cancer pharmaceutical safety -- Anatomy of Risk Evaluation and Mitigation Strategies (REMS) -- Cancer Drug Toxicity: Moving from patient to Survivor.
520	3		_aCancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety. Identifying and understanding high-priority policy issues and key pharmacovigilance strategies is of paramount importance. In this volume, outstanding and original chapters provide an overview and synthesis of the latest thoughts and findings relating to drug safety in the cancer domain. Topics include natural language processing and pharmacovigilance of alternative cancer pharmaceuticals. The information presented in this volume will improve understanding of emerging strategies to identify adverse drug reactions and drug-drug interactions within the cancer setting and will highlight policies that have been instituted to improve cancer patient safety. In summary, Cancer Policy: Pharmaceutical Safety explores many of the important areas of pharmacovigilance research in oncology.
988			_aSpringer_Medicine_2019
650		7	_aCáncer _2embne _9174085 _xTratamiento
650		7	_aMedicamentos _9331970 _2embne _xEnsayos clínicos
700	1		_aMcKoy, June M. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aWest, Dennis P. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service) _9106996
776	0	8	_iPrinted edition: _z9783319438948
776	0	8	_iPrinted edition: _z9783319438955
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-43896-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_dz _feng _ggw _h0 _b02/2023 _eb _zSI